USPTO 2015–2025 USPTO PatentsView US Corporation

Epitel, Inc.

USPTO PatentsView assignee record - 14 granted patents across 5 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).

The verdict

According to USPTO PatentsView, Epitel ranks #19,725 of 50,000 tracked US assignees by granted-patent volume, with 14 patents across 5 technology areas.

#19,725
of 50,000 US assignees by volume
Top 16%
by Innovation Score (48.8/100)
19.2
avg claims per patent

USPTO PatentsView assignee plate

Corpus R19725 · US Corporation #19,725 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 14 grants
  • MID-PACK #19,725/50,000
  • PHOTO-FINISH Elmich Pte
  • CPC-NARROW A61B · 5 areas
  • INNOV-PAR 48.8/100
  • CLAIMS-RICH 19.2 claims/avg
  • TYPE-USCORP US Corporation
  • SPAN-YRS 2021–2025 · 5y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Elmich Pte Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Epitel

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Epitel, Inc. stamps GRANTS-MICRO, MID-PACK, PHOTO-FINISH, CPC-NARROW, INNOV-PAR, CLAIMS-RICH, TYPE-USCORP, SPAN-YRS, BOOK-RICH. Volume places it #19,725 of 50,000; Innovation Score 48.8/100 sits in the top 16% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Elmich Pte Ltd (±0 grants).

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Portfolio overview

Epitel, Inc. has been granted 14 US utility patents between 2021 and 2025, placing Epitel, Inc. at #19,725 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.2 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Epitel, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Epitel sits between Elmich Pte Ltd (14 patents, rank #19,736) and Essentium Inc. (14 patents, rank #19,744) - the closest US assignees by grant volume. The composite Innovation Score of 48.8/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Historical data spans 2021 through 2025, with 14 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Epitel, Inc.'s 19.2 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 5 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Epitel's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Epitel holds 14 patents at rank #19,740, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Epitel

By rank, the assignees closest to #19,740 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Epitel's primary technology class.

Epitel's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 2021202320242025 3
USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Epitel, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 7.1%
2023 5 35.7%
2024 5 35.7%
2025partial year 3 21.4%

Where it ranks

Overall rank by patents

#19,725

of 50,000 tracked assignees

Innovation Score

48.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.